A simple blood test might be available soon that can speed the diagnosis of Alzheimer’s disease.

No single diagnostic test tells a physician that a patient has Alzheimer’s. However, medical histories can be taken, cognitive tests given, and other physical and neurological exams might hone in on dementia in general. https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests.

Blood Test for Alzheimer’s Disease (AD)

https://www.nbcnews.com/health/aging/first-blood-test-help-diagnose-alzheimer-s-goes-sale-n1249355. C2N Diagnostics of St. Louis developed a blood test aimed at those over 60 years of age having cognitive problems. This test has not been approved by the FDA. It is being used as a screening test before more expensive testing – brain scans, PET scans, etc. Some scans are not covered by insurance.

The Blood Test

https://c2n.com/. The Precivity AD blood test for detecting AD with mass spectrometry. Plasma concentrations of amyloid-betas 42 and 40 are compared with the apolipoprotein E (ApoE) proteotype. The amyloid-beta 42/40 ratio determines the ApoE genotype, which then is statistically assessed to patient age and specific probabilities associated with known AD progression.
This test is not covered by insurance or Medicare. C2N Diagnostics charges $1250. The process takes about ten days once a sample is in their system.


https://radiology.ucsf.edu/patient-care/services/specialty-imaging/alzheimer. The current gold standard for Alzheimer’s diagnosis is the amyloid PET scan. A buildup of amyloid-beta plaque can be seen using a radioactive dye. The amyloid PET scan combined with the Precivity AD blood test is approximately 92 percent accurate at this time. The Alzheimer’s Association is awaiting FDA approval before endorsing this blood test.


No one will argue that the earlier any disease can be diagnosed correctly, the better the chance to treating it successfully. However, the time and expense of current methods of AD diagnosis yield relative results depending on the number of tests run. This test is currently available only for those with cognitive issues over 60.

I am confident that more extensive clinical studies of this blood test will allow the FDA to approve its use specifically for AD testing.

Live Longer & Enjoy Life! – Red O’Laughlin – RedOLaughlin.com


2 Responses

Leave a Reply

Your email address will not be published. Required fields are marked *